Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses
Abstract
In the phase 3 trial Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy, apixaban was noninferior to enoxaparin, overlapped and followed by warfarin, in the treatment of venous thromboembolism (VTE) with significantly less bleeding; in a real-world evaluation, risks for bleeding and recurrent VTE were lower with apixaban vs warfarin plus parenteral anticoagulant (PAC) bridge therapy. The...
Paper Details
Title
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses
Published Date
Jan 28, 2020
Journal
Volume
4
Issue
2
Pages
432 - 439
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History